Research Analysts Offer Predictions for Lexeo Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:LXEO)

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Equities researchers at Leerink Partnrs lowered their Q1 2024 earnings per share estimates for Lexeo Therapeutics in a research report issued on Tuesday, April 23rd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($1.10) per share for the quarter, down from their prior estimate of ($1.09). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.03) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q2 2024 earnings at ($1.09) EPS, Q3 2024 earnings at ($1.09) EPS, Q4 2024 earnings at ($1.08) EPS, FY2024 earnings at ($4.36) EPS, FY2025 earnings at ($4.39) EPS and FY2026 earnings at ($4.51) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its earnings results on Monday, March 11th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.15).

Lexeo Therapeutics Stock Down 2.7 %

Shares of NASDAQ:LXEO opened at $12.16 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.21. Lexeo Therapeutics has a 12-month low of $9.00 and a 12-month high of $22.33. The firm’s 50 day moving average is $14.37.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Omega Fund Management LLC bought a new stake in Lexeo Therapeutics during the fourth quarter worth $28,955,000. Blackstone Inc. bought a new stake in Lexeo Therapeutics during the fourth quarter worth $9,342,000. Finally, Eventide Asset Management LLC bought a new stake in Lexeo Therapeutics during the fourth quarter worth $40,298,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.